MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals Inc. is poised for significant revenue growth, with estimates projecting its core business revenues to exceed $1 billion, driven by strong sales of its flagship product, Livmarli, expected to reach over $800 million by 2031. The company's fiscal year 2025 projections indicate Livmarli sales of approximately $360 million, representing a 69% year-over-year growth, primarily fueled by increased patient additions in Alagille Syndrome and robust expansion within the adult PFIC population. Furthermore, the potential for additional revenue from pipeline programs and the successful outcomes of ongoing studies suggest a favorable long-term outlook for Mirum Pharmaceuticals as it continues to expand its market presence in rare and orphan diseases.

The negative outlook on Mirum Pharmaceuticals's stock is primarily driven by heightened operational risks, including potential safety events associated with its products and greater-than-expected cash burn, which could necessitate more frequent equity issuances at less favorable valuations. Additionally, slower-than-anticipated growth of its main product, Livmarli, coupled with the risk of failure of its pipeline assets and increased competition, may undermine the company's market share and pricing power. Regulatory challenges, including potential delays or failures in obtaining approvals for its developmental candidates, further exacerbate the uncertainties surrounding Mirum's ability to generate future revenues.